IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USAGlobeNewsWire • 06/22/23
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 06/20/23
Merck: Approaching The Accumulation Phase With An Expanding Product PortfolioSeeking Alpha • 06/17/23
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 06/16/23
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)Business Wire • 06/13/23
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?Zacks Investment Research • 06/13/23
Merck & Co., Inc. (MRK) Goldman Sachs 44th Annual Global Healthcare ConferenceSeeking Alpha • 06/13/23
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023Business Wire • 06/12/23
FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract CancerBusiness Wire • 06/08/23
Merck is suing the government over Medicare drug prices—what retirees need to knowMarket Watch • 06/06/23